RECRUITINGOBSERVATIONAL

Ocular Complications From Cancer Therapy - Patient Registry and Biobank

Registry and Biobank of Patients With a History of Cancer Therapy

About This Trial

The purpose of this study is to collect data on patients seen at University of Maryland after undergoing cancer therapy. Previous medications, ocular history, medical history, clinical evaluations, surgical procedures and outcomes will be gathered on the patients who consent to participate. Potential subjects will be enrolled from the clinical practice of the investigator at the time of their eye examination visit. A standard of care exam will be performed pertinent to the reason for the visit. In addition to the standard of care exam, certain biological specimens (ocular surface wash, mucocellular material, corneal filaments, impression cytology, and/or blood) will be collected, stored, and analyzed to obtain immunologic, cellular, or molecular mechanistic insights into disease pathogenesis.

Who May Be Eligible (Plain English)

Inclusion Criteria for the Cancer Therapy Group: - Adult patients (greater than 18 years of age) - Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery) - Patients who have a history of allogenic HSCT with all stem cell sources including bone marrow, PBSC, cord AND/OR patients with a history of prior cancer therapy including BMT, chemotherapy, and immunotherapy - Patients will be recruited after their HSCT or cancer therapy at their ophthalmology appointment - Patients can be included with a history of prior cancer therapy including chemotherapy, BMT, immunotherapy. Prior cancer therapy must be identified and documented. - The patient must be able to understand and sign and date the willing to sign a consent form form approved by the IRB. Inclusion Criteria for the Control Group: - No history of cancer or cancer therapy in the past - Adult patients (greater than 18 years of age) - Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery) - The patient must be able to understand and sign and date the willing to sign a consent form form approved by the IRB. Exclusion Criteria for the Cancer Therapy Group: - Vulnerable populations: neonates, children, prisoners, institutionalized individuals - Inability or refusal to provide willing to sign a consent form. - History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma). Exclusion Criteria for the Control Group: - Vulnerable populations: neonates, children, prisoners, institutionalized individuals - Inability or refusal to provide willing to sign a consent form. - History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma). - History of cancer or cancer therapy including chemotherapy, immunotherapy, BMT. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria for the Cancer Therapy Group: * Adult patients (greater than 18 years of age) * Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery) * Patients who have a history of allogenic HSCT with all stem cell sources including bone marrow, PBSC, cord AND/OR patients with a history of prior cancer therapy including BMT, chemotherapy, and immunotherapy * Patients will be recruited after their HSCT or cancer therapy at their ophthalmology appointment * Patients can be included with a history of prior cancer therapy including chemotherapy, BMT, immunotherapy. Prior cancer therapy must be identified and documented. * The patient must be able to understand and sign and date the informed consent form approved by the IRB. Inclusion Criteria for the Control Group: * No history of cancer or cancer therapy in the past * Adult patients (greater than 18 years of age) * Deny a history of eye diseases (excluding cataract, glaucoma, mild dry eye disease, or history of cataract or refractive surgery) * The patient must be able to understand and sign and date the informed consent form approved by the IRB. Exclusion Criteria for the Cancer Therapy Group: * Vulnerable populations: neonates, children, prisoners, institutionalized individuals * Inability or refusal to provide informed consent. * History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma). Exclusion Criteria for the Control Group: * Vulnerable populations: neonates, children, prisoners, institutionalized individuals * Inability or refusal to provide informed consent. * History of ocular surgery or ocular disease (except refractive or cataract surgery, mild dry eye disease, or glaucoma). * History of cancer or cancer therapy including chemotherapy, immunotherapy, BMT.

Treatments Being Tested

PROCEDURE

Eye exam

Previous medications, ocular history, medical history, clinical evaluations, surgical procedures and outcomes will be gathered on the patients who consent to participate. A standard of care exam will be performed to the reason for the visit. In addition to the standard of care exam, those in the Cancer Therapy arm will have certain biological samples (tear collection, impression cytology, and/or blood) collected, stored, and analyzed so we may obtain immunologic, cellular, or molecular mechanistic insights into disease pathogenesis.

Locations (1)

Stoler Outpatient Cancer Center at the University of Maryland

Baltimore, Maryland, United States